Companies · Biotechnology

Locus Solutions, LLC/OH

SOLON · Biotechnology

Diligence memoA one-page analyst read on Locus Solutions, LLC/OH — recommendation, valuation, rhythm, risks.
$25.0M
Total raised · real
2
Rounds
0.2×
Latest step-up
Top 29%
Sector rank · raised
Series B
Latest stage · inferred · Mon May 09 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Locus Solutions, LLC/OH looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.51× the median modeled value of Series B Biotechnology companies in 2022–2024 (197 peers) — value vs value, same stage and era.
Dormant
  • Last raise 4.1 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Locus Solutions, LLC/OH behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
6.6 yr record
Peak capital year was 2019 with $20.3M across 1 filings.
Market position
ahead of 72% of Biotechnology peers
Capital scale is ahead of 72% of Biotechnology peers; modeled value is above 55% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2019: $20.3M across 1 filings.
  • Largest single filing was $20.3M on 2019-11-21.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Locus Solutions, LLC/OH is one of 4293 Biotechnology companies tracked from SOLON. By capital raised it ranks in the upper tier (ahead of 72% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
15
Investors (latest)
2022-05-09
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BSeries B · 2019-11-21 Raised $20M (real) Modeled valuation $805M (est)$20M$805MSeries B2019Series B · 2022-05-09 Raised $4.7M (real) Modeled valuation $85M (est)$4.7M$85MSeries B2022+$4.7MCumulative $25M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series B$20.3M · 2019
Series B extension$4.7M · 2022

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 25%.

Modeled valuation trajectory
$84.9M
Base estimate est.
$9.5M
Conservative case
$229.1M
Upside case
$26.3M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series B · modeled $805.2M · 2019-11-212019Series B · modeled $84.9M · 2022-05-092022
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
54%
Survival probability
36% low · 66% high
1.54×/yr
Annual markup
1.86×/yr upside case
4.2 yr
Elapsed time used
4.2 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
30 mo
Avg between rounds
$10.2M/yr
Capital velocity
6.6 yr
On record since
2019
First round
2
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 3.5× above median
This company$25.0M
Sector median$7.2M
Latest round — vs other Series B rounds in sector (real $, this stage) 0.3× of median
This company$4.7M
Sector median$17.5M
Modeled value — vs sector median (estimate, all stages) 1.3× above median
This company$84.9M
Sector median$64.2M

Raised more than 72% of sector peers (real $). Modeled value above 55% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #137 of 197.

This companyCohort peer
$10.0M$100.0M$1.0B$10.0M$100.0M$1.0BCapital raised (log)Mt McKinley Medical Holding Corp USA · Series B Raised $40.0M · modeled $738.4M (est)YAP Therapeutics Inc · Series B Raised $30.1M · modeled $618.3M (est)Pinteon Therapeutics, Inc. · Series B Raised $39.2M · modeled $603.8M (est)OncXerna Therapeutics, Ltd. · Series B Raised $30.0M · modeled $591.4M (est)EpiBiologics, Inc. · Series B Raised $30.0M · modeled $570.2M (est)GIOGI Ltd · Series B Raised $27.3M · modeled $554.5M (est)SonoThera, Inc. · Series B Raised $30.4M · modeled $550.9M (est)Perceive Biotherapeutics, Inc. · Series B Raised $40.0M · modeled $544.6M (est)GIOCAN Ltd · Series B Raised $24.5M · modeled $498.6M (est)GIODIA Ltd · Series B Raised $24.5M · modeled $498.6M (est)GIOHEALTH Ltd · Series B Raised $24.5M · modeled $498.6M (est)Cerapedics Inc · Series B Raised $99.1M · modeled $492.3M (est)Locus Solutions, LLC/OH (this company) Raised $25.0M · modeled $84.9M (est)Locus Solutions, LLC/OH
CompanyStageRaised · realValue · estvs peer med.
Mt McKinley Medical Holding Corp USASeries B$40.0M$738.4M4.41×
YAP Therapeutics IncSeries B$30.1M$618.3M3.69×
Pinteon Therapeutics, Inc.Series B$39.2M$603.8M3.60×
OncXerna Therapeutics, Ltd.Series B$30.0M$591.4M3.53×
EpiBiologics, Inc.Series B$30.0M$570.2M3.40×
GIOGI LtdSeries B$27.3M$554.5M3.31×
SonoThera, Inc.Series B$30.4M$550.9M3.29×
Perceive Biotherapeutics, Inc.Series B$40.0M$544.6M3.25×
GIOCAN LtdSeries B$24.5M$498.6M2.97×
GIODIA LtdSeries B$24.5M$498.6M2.97×
GIOHEALTH LtdSeries B$24.5M$498.6M2.97×
Cerapedics IncSeries B$99.1M$492.3M2.94×
Locus Solutions, LLC/OH this companySeries B$25.0M$84.9M0.51×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series B$20.3M2019-11-21$112.7M$805.2M90%
Series B$4.7M2022-05-09$26.3M$84.9M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series B$20.3M2019-11-21
    • First recorded raise — entered as Series B.
    • 65 investors on this round.
  2. Series B$4.7M2022-05-09
    • Raised again after 30 mo — slower than the ~14 mo sector norm.
    • Round 4.3× smaller than the prior — bridge or down round.
    • 15 investors on this round.
Intelligence
2024 ~Q4
Modeled next raise · ~30mo cadence
$4.7M
Modeled next size est.range $4.7M$7.6M
0.2×
Last step-up
$10.2M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Donald M. Sweeney1 other2019-11
Alvaro M. Pascotto2019-11
Alvaro M Pascottto2022-05
Andrew M Lefkowitz2019-11
David M Heidecorn2019-11
Donald M Sweeny2022-05
John M Rea2019-11
Karthik M Karathur2022-05
Karthik N. Karathur2019-11
Sean M Farmer2019-11
Tom M Vetrano2019-11
Registry & provenance

Locus Solutions, LLC/OH is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1808957
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Lonestar Medicines, Inc.BiotechnologySeries B$25.0M$92.4Msame sector · same stage
Angiex, Inc.BiotechnologySeries B$24.9M$98.6Msame sector · same stage
Insite Vision IncBiotechnologySeries B$24.6M$94.5Msame sector · same stage
Brainbox Solutions, Inc.BiotechnologySeries B$26.0M$67.8Msame sector · same stage
Polarityte, Inc.BiotechnologySeries B$24.0M$69.4Msame sector · same stage
Promaxo Holdings, Inc.BiotechnologySeries B$26.8M$92.0Msame sector · same stage
Pacegenix, Inc.BiotechnologySeries B$22.5M$77.8Msame sector · same stage
Ramona Optics, Inc.BiotechnologySeries B$27.9M$91.4Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Locus Biosciences, Inc.BiotechnologySeries B$213.3M91%
Gene Solutions LlcBiotechnologySeries A$192.7M86%
Ufovax, LLCBiotechnologySeries A$363.3M83%
MyGenetics LLCBiotechnologyPre-Seed$10.5M83%
Bugworks Research, Inc.BiotechnologySeries B$56.4M83%
Mosaic Biosciences, Inc.BiotechnologySeries A$176.4M82%
Chemical Solutions Group, LLCBiotechnologySeries A$361.5M82%
Portal Biotechnologies, Inc.BiotechnologySeries A$49.5M81%
Frequently asked
How much funding has Locus Solutions, LLC/OH raised?
Locus Solutions, LLC/OH has raised approximately $25.0M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Locus Solutions, LLC/OH's estimated valuation?
Provath's modeled valuation for Locus Solutions, LLC/OH is approximately $84.9M (modeled range $9.5M–$229.1M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Locus Solutions, LLC/OH at?
Locus Solutions, LLC/OH's latest modeled financing stage is Series B. Its most recent recorded round closed around Mon May 09.
What does Locus Solutions, LLC/OH do and where is it based?
Locus Solutions, LLC/OH operates in the Biotechnology sector, based in SOLON.
Explore related

See where Locus Solutions, LLC/OH sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Locus Solutions, LLC/OH, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.